Beth Hoffman

Beth Hoffman

Company: Origami Therapeutics

Job title: Founder, President & Chief Executive Officer


Exploring CNS Application of Protein Degraders to Determine Whether They Can be Utilized in a Selective Manner to Minimize Side Effects & Maximize Therapeutic Outcome 4:00 pm

Deep diving into targeted protein degraders (TPDs) from neurodegenerative therapeutic perspective Exploring the use of TPDs to minimize side effects and maximize therapeutic outcome Deep diving into the future of TPDs in CNS disorders to determine their impact on the CNS therapeutic landscapeRead more

day: Day 2 afternoon

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.